Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Bladder Cancer

  Free Subscription


1 Abdom Radiol (NY)
1 Acta Chir Belg
1 Actas Urol Esp (Engl Ed)
3 Ann Diagn Pathol
1 Ann Med
1 Ann Oncol
2 Anticancer Res
1 Antioxidants (Basel)
1 ANZ J Surg
1 Asian Pac J Cancer Prev
2 Biomedicines
1 Biosci Rep
1 BJU Int
1 BMC Urol
1 Br J Cancer
1 Cancer Immunol Immunother
6 Cancer Med
6 Cancers (Basel)
1 Cells
1 Clin Transl Med
1 Clin Transl Oncol
1 Comb Chem High Throughput Screen
1 Commun Biol
1 Curr Oncol Rep
1 Endocr Metab Immune Disord Drug Targets
1 Epidemiol Prev
1 Eur J Surg Oncol
2 Eur Urol
1 Front Immunol
1 Front Oncol
1 Genet Test Mol Biomarkers
1 Georgian Med News
1 Hinyokika Kiyo
1 IET Syst Biol
1 Indian J Cancer
3 Int J Mol Sci
2 Int Urol Nephrol
2 J Clin Med
1 J Immunother Cancer
1 JAMA Netw Open
1 JCO Precis Oncol
1 Molecules
1 Pan Afr Med J
1 Pathol Oncol Res
1 Pathologica
1 Pediatr Blood Cancer
1 Plant Foods Hum Nutr
1 PLoS One
1 Pol Arch Intern Med
1 Radiother Oncol
1 Retin Cases Brief Rep
2 Scand J Urol
1 Sci Adv
1 Technol Cancer Res Treat
1 Tohoku J Exp Med
1 Urol Case Rep
1 Urol Oncol
1 Urologia
2 World J Surg Oncol
4 World J Urol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Abdom Radiol (NY)

  1. HU X, Wang K, Sun M, Li C, et al
    Quantitative MRI in distinguishing bladder paraganglioma from bladder leiomyoma.
    Abdom Radiol (NY). 2023;48:1051-1061.
    PubMed         Abstract available

    Acta Chir Belg

  2. BORET S, Lambert E, Charles VP, Philippe T, et al
    Vulvar pagetoid urothelial intraepithelial neoplasia: a case report.
    Acta Chir Belg. 2023;123:174-177.
    PubMed         Abstract available

    Actas Urol Esp (Engl Ed)

    BCG unresponsive non-muscle invasive bladder cancer: The beginning of a new era?
    Actas Urol Esp (Engl Ed). 2023 Feb 24:S2173-5786(23)00018.

    Ann Diagn Pathol

  4. SYED M, Mushtaq S, Loya A, Hassan U, et al
    Prognostic significance of minor high grade component in non-invasive papillary urothelial carcinoma of urinary bladder: (A study of 273 consecutive cases over a period of 3 years).
    Ann Diagn Pathol. 2023;63:152079.
    PubMed         Abstract available

  5. BABAN F, Auen T, Eschbacher KL, Swanson AA, et al
    Invasive urothelial carcinoma with squamous differentiation and associated high-risk human papilloma virus infection: Clinical, cytologic, and histologic features of a rare entity.
    Ann Diagn Pathol. 2023;63:152103.
    PubMed         Abstract available

  6. PEREZ-MONTIEL D, Olivares-Mundo A, Jimenez-Rios MA, Morera CS, et al
    Influence of luminal and basal subtype in prognosis of high-grade non muscle invasive urothelial carcinoma.
    Ann Diagn Pathol. 2023;63:152081.
    PubMed         Abstract available

    Ann Med

  7. YU Z, Lu C, Lai Y
    A serum miRNAs signature for early diagnosis of bladder cancer.
    Ann Med. 2023;55:736-745.
    PubMed         Abstract available

    Ann Oncol

  8. BALAR AV, Castellano DE, Grivas P, Vaughn DJ, et al
    Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
    Ann Oncol. 2023;34:289-299.
    PubMed         Abstract available

    Anticancer Res

  9. LI JR, Wang SS, Lu K, Chen CS, et al
    First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study.
    Anticancer Res. 2023;43:1331-1339.
    PubMed         Abstract available

  10. CHEN SY, Chao CN, Huang HY, Zhao PW, et al
    Artesunate Exhibits Synergy With Cisplatin and Cytotoxicity for Upper Tract and Bladder Urothelial Carcinoma Cells.
    Anticancer Res. 2023;43:1175-1184.
    PubMed         Abstract available

    Antioxidants (Basel)

  11. GALINIAK S, Molon M, Biesiadecki M, Mokrzynska A, et al
    Oxidative Stress Markers in Urine and Serum of Patients with Bladder Cancer.
    Antioxidants (Basel). 2023;12:277.
    PubMed         Abstract available

    ANZ J Surg

  12. CHAU M, Thia I, Viswambaram P, Hawks C, et al
    Lymph node assessment technique matters in radical cystectomy for bladder cancer.
    ANZ J Surg. 2023 Mar 3. doi: 10.1111/ans.18292.
    PubMed         Abstract available

    Asian Pac J Cancer Prev

  13. YOUSSIEF MOHAMMED AA, Gamal DA, Abd Elzaher AR, Hasaballah A, et al
    Trimodality Therapy in which Concurrent Chemoradiation with Concomitant Boost in Muscle Invasive TCC Urinary Bladder Cancer.
    Asian Pac J Cancer Prev. 2023;24:517-524.
    PubMed         Abstract available


  14. JAIN M, Tivtikyan A, Kamalov D, Avdonin S, et al
    Development of a Sensitive Digital Droplet PCR Screening Assay for the Detection of GPR126 Non-Coding Mutations in Bladder Cancer Urine Liquid Biopsies.
    Biomedicines. 2023;11:495.
    PubMed         Abstract available

  15. SHI Y, Mathis BJ, He Y, Yang X, et al
    The Current Progress and Future Options of Multiple Therapy and Potential Biomarkers for Muscle-Invasive Bladder Cancer.
    Biomedicines. 2023;11:539.
    PubMed         Abstract available

    Biosci Rep

  16. Retraction: CircRNA circPDSS1 promotes bladder cancer by downregulating miR-16.
    Biosci Rep. 2023;43:BSR-2019-1961.

    BJU Int

  17. NURMINEN P, Ettala O, Uusitalo-Seppala R, Hogerman M, et al
    Clinical presentation of bacille Calmette-Guerin (BCG) infections after BCG instillation therapy.
    BJU Int. 2023;131:306-312.
    PubMed         Abstract available

    BMC Urol

  18. LI X, Fu C, Li G, He H, et al
    RNA-seq reveals novel mechanistic targets of Livin in bladder cancer.
    BMC Urol. 2023;23:26.
    PubMed         Abstract available

    Br J Cancer

  19. VASDEV N
    Multicentric validation of nomograms based on BC-116 and BC-106 urine peptide biomarker panels for bladder cancer diagnostics and monitoring in two prospective cohorts of patients.
    Br J Cancer. 2023 Mar 1. doi: 10.1038/s41416-023-02142.

    Cancer Immunol Immunother

  20. SONPAVDE GP, Maughan BL, McGregor BA, Wei XX, et al
    Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma.
    Cancer Immunol Immunother. 2023;72:775-782.
    PubMed         Abstract available

    Cancer Med

  21. ITO K, Kita Y, Yokomizo A, Miki J, et al
    Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study.
    Cancer Med. 2023;12:2325-2332.
    PubMed         Abstract available

  22. WU Y, Zhu W, Wang J, Liu L, et al
    Using machine learning for mortality prediction and risk stratification in atezolizumab-treated cancer patients: Integrative analysis of eight clinical trials.
    Cancer Med. 2023;12:3744-3757.
    PubMed         Abstract available

  23. HUANG J, Huang D, Ruan X, Huang J, et al
    Association between cannabis use with urological cancers: A population-based cohort study and a mendelian randomization study in the UK biobank.
    Cancer Med. 2023;12:3468-3476.
    PubMed         Abstract available

  24. MATSUBARA N, Yonese J, Kojima T, Azuma H, et al
    Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma.
    Cancer Med. 2023;12:2761-2771.
    PubMed         Abstract available

  25. LIMONNIK V, Samiei A, Abel S, Wegner RE, et al
    Urachal carcinoma: A novel staging system utilizing the National Cancer Database.
    Cancer Med. 2023;12:2752-2760.
    PubMed         Abstract available

  26. ALRADHI M, Wen S, Safi M, Al-Danakh A, et al
    Molecular genetic and clinical characteristic analysis of primary signet ring cell carcinoma of urinary bladder identified by a novel OR2L5 mutation.
    Cancer Med. 2023;12:3931-3951.
    PubMed         Abstract available

    Cancers (Basel)

  27. ABOUDARAM A, Chaltiel L, Pouessel D, Graff-Cailleaud P, et al
    Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients with No Progression and with No More than Five Residual Metastatic Lesions Following First-Line Systemic Therapy: A Retrospective Analysis.
    Cancers (Basel). 2023;15:1161.
    PubMed         Abstract available

  28. LEE HW, Kwon WA, Nguyen NT, Phan DTT, et al
    Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Possibilities and Limitations.
    Cancers (Basel). 2023;15:1323.
    PubMed         Abstract available

  29. LEE MC, Wang SY, Pan CT, Chien MY, et al
    Development of Deep Learning with RDA U-Net Network for Bladder Cancer Segmentation.
    Cancers (Basel). 2023;15:1343.
    PubMed         Abstract available

  30. LIN PT, Hung WK, Chang YH, Hsieh ML, et al
    Replacement Instead of Discontinuation of Bacillus Calmette-Guerin Instillation in Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2023;15:1345.
    PubMed         Abstract available

  31. GAO Y, Cao H, Huang D, Zheng L, et al
    RNA-Binding Proteins in Bladder Cancer.
    Cancers (Basel). 2023;15:1150.
    PubMed         Abstract available

  32. WANG H, Feng Y, Zheng X, Xu X, et al
    The Diagnostic and Therapeutic Role of snoRNA and lincRNA in Bladder Cancer.
    Cancers (Basel). 2023;15:1007.
    PubMed         Abstract available


  33. KOLL FJ, Metzger E, Hamann J, Ramos-Triguero A, et al
    Overexpression of KMT9alpha Is Associated with Aggressive Basal-like Muscle-Invasive Bladder Cancer.
    Cells. 2023;12:589.
    PubMed         Abstract available

    Clin Transl Med

  34. XU H, Liu Z, Weng S, Ren Y, et al
    Epigenetically regulated gene expression profiles recognized three molecular classifications with prognostic and therapeutic implications in bladder cancer.
    Clin Transl Med. 2023;13:e1145.

    Clin Transl Oncol

  35. BOROWCZAK J, Szczerbowski K, Maniewski M, Zdrenka M, et al
    The prognostic role of p53 and its correlation with CDK9 in urothelial carcinoma.
    Clin Transl Oncol. 2023;25:830-840.
    PubMed         Abstract available

    Comb Chem High Throughput Screen

  36. WANG W, Chen L, Yang J, Hu D, et al
    Apatinib Inhibits Bladder Cancer through Suppression of The VEGFR2-PI3K-AKT Signaling Pathway as revealed by Network Pharmacology and In Vitro Experimental Verification.
    Comb Chem High Throughput Screen. 2023.
    PubMed         Abstract available

    Commun Biol

  37. MARTINEZ-VIDAL L, Chighizola M, Berardi M, Alchera E, et al
    Micro-mechanical fingerprints of the rat bladder change in actinic cystitis and tumor presence.
    Commun Biol. 2023;6:217.
    PubMed         Abstract available

    Curr Oncol Rep

  38. BOULEFTOUR W, Sargos P, Magne N
    Nectin-4: a Tumor Cell Target and Status of Inhibitor Development.
    Curr Oncol Rep. 2023;25:181-188.
    PubMed         Abstract available

    Endocr Metab Immune Disord Drug Targets

  39. FENG R, Li Z, Ge G, Wang C, et al
    Cancer-associated fibroblast-derived extracellular vesicles mediate immune escape of bladder cancer via PD-L1/PD-1 expression.
    Endocr Metab Immune Disord Drug Targets. 2023.
    PubMed         Abstract available

    Epidemiol Prev

  40. ZONA A, Fazzo L, Benedetti M, Bruno C, et al
    [SENTIERI - Epidemiological Study of Residents in National Priority Contaminated Sites. Sixth Report].
    Epidemiol Prev. 2023;47.
    PubMed         Abstract available

    Eur J Surg Oncol

  41. MOEEN AM, Behnsawy HM, Faragallah MA, Gadelkareem RA, et al
    Functional evaluation of a spiral neobladder with an angled chimney; A prospective randomized comparative study.
    Eur J Surg Oncol. 2023;49:491-496.
    PubMed         Abstract available

    Eur Urol

  42. SYLVESTER RJ, Rodriguez O, Hernandez V, Turturica D, et al
    Erratum to "European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel
    Eur Urol. 2023 Feb 23:S0302-2838(23)02579-4. doi: 10.1016/j.eururo.2023.

  43. STENZL A, Roupret M, Witjes JA, Gontero P, et al
    High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation.
    Eur Urol. 2023;83:193-194.
    PubMed         Abstract available

    Front Immunol

  44. TANG Q, Zuo W, Wan C, Xiong S, et al
    Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
    Front Immunol. 2023;13:1097730.
    PubMed         Abstract available

    Front Oncol

  45. WOLF P
    Inhibitor of apoptosis proteins as therapeutic targets in bladder cancer.
    Front Oncol. 2023;13:1124600.
    PubMed         Abstract available

    Genet Test Mol Biomarkers

  46. WANG XF, Liu DL, Geng L
    The PSCA rs2294008 (C/T) Polymorphism Increases the Risk of Gastric and Bladder Cancer: A Meta-Analysis.
    Genet Test Mol Biomarkers. 2023;27:44-55.
    PubMed         Abstract available

    Georgian Med News

  47. IMAMVERDIYEV S, Qasimov E, Naghiyev R
    Georgian Med News. 2023;:98-102.
    PubMed         Abstract available

    Hinyokika Kiyo

  48. IKEDA M, Uemura K, Araki Y, Iribe Y, et al
    [A Case of Long-Term Survival Following Multidisciplinary Therapy for Small Intestinal Metastasis of Bladder Cancer].
    Hinyokika Kiyo. 2023;69:55-58.
    PubMed         Abstract available

    IET Syst Biol

  49. LI SH, Zhai GQ, He RQ, Chen G, et al
    Down-regulation and clinical significance of Sorbin and SH3 domain-containing protein 1 in bladder cancer tissues.
    IET Syst Biol. 2023 Feb 28. doi: 10.1049/syb2.12060.
    PubMed         Abstract available

    Indian J Cancer

  50. TACAR SY, Yilmaz M, Baytekin HF, Tural D, et al
    Evaluation of predictive factors in patients with bladder cancer undergoing atezolizumab treatment: Case reports.
    Indian J Cancer. 2022;59:556-559.
    PubMed         Abstract available

    Int J Mol Sci

  51. YANG CC, Chuang FC, Chang CL, Huang CR, et al
    Melatonin-Assisted Cisplatin Suppresses Urinary Bladder Cancer Cell Proliferation and Growth through Inhibiting PrP(C)-Regulated Cell Stress and Cell Proliferation Signaling.
    Int J Mol Sci. 2023;24:3353.
    PubMed         Abstract available

  52. BOSCHI F, Malatesta M
    Nanoparticle-Based Techniques for Bladder Cancer Imaging: A Review.
    Int J Mol Sci. 2023;24:3812.
    PubMed         Abstract available

  53. SANGUEDOLCE F, Zanelli M, Palicelli A, Bisagni A, et al
    HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role.
    Int J Mol Sci. 2023;24:3720.
    PubMed         Abstract available

    Int Urol Nephrol

  54. QIU Y, Zhang X, Dong Z, Zhang Y, et al
    Comparable survival benefits of partial ureterectomy to radical nephroureterectomy in non-metastatic ureter carcinoma: a population-matched study.
    Int Urol Nephrol. 2023;55:579-588.
    PubMed         Abstract available

  55. DEWITT-FOY ME, Anele UA, Accioly JPE, Sharpe MG, et al
    Cancer risk in bladder diverticula: a large institutional analysis of risk and management.
    Int Urol Nephrol. 2023;55:541-546.
    PubMed         Abstract available

    J Clin Med

  56. LEMINSKI A, Michalski W, Masojc B, Kaczmarek K, et al
    Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review.
    J Clin Med. 2023;12:1560.
    PubMed         Abstract available

  57. WEN P, Wen J, Huang X, Wang F, et al
    Development and Validation of Nomograms Predicting the 5- and 8-Year Overall and Cancer-Specific Survival of Bladder Cancer Patients Based on SEER Program.
    J Clin Med. 2023;12:1314.
    PubMed         Abstract available

    J Immunother Cancer

  58. JOSHI M, Tuanquin L, Zhu J, Walter V, et al
    Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023.
    J Immunother Cancer. 2023;11:e006551.
    PubMed         Abstract available

    JAMA Netw Open

  59. MCELREE IM, Steinberg RL, Mott SL, O'Donnell MA, et al
    Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guerin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer.
    JAMA Netw Open. 2023;6:e230849.
    PubMed         Abstract available

    JCO Precis Oncol

  60. KERIOUI M, Bertrand J, Desmee S, Le Tourneau C, et al
    Assessing the Increased Variability in Individual Lesion Kinetics During Immunotherapy: Does It Exist, and Does It Matter?
    JCO Precis Oncol. 2023;7:e2200368.
    PubMed         Abstract available


  61. LIU Z, Song L, Xie J, Wu XR, et al
    Kavalactone Kawain Impedes Urothelial Tumorigenesis in UPII-Mutant Ha-Ras Mice via Inhibition of mTOR Signaling and Alteration of Cancer Metabolism.
    Molecules. 2023;28:1666.
    PubMed         Abstract available

    Pan Afr Med J

  62. MAJA SG, Slavica KK, Suad A, Rubens J, et al
    Bladder mucinous adenocarcinoma as a diagnostic challenge: a case report.
    Pan Afr Med J. 2022;42:221.
    PubMed         Abstract available

    Pathol Oncol Res

  63. WANG Z, Wang J, Zhang W, Wang D, et al
    Case report: Urothelial carcinoma of the renal pelvis with trophoblastic differentiation: A rare case report and review of literature.
    Pathol Oncol Res. 2023;29:1610856.
    PubMed         Abstract available


  64. RASPOLLINI MR, Comperat EM, Lopez-Beltran A, Montironi R, et al
    News in the classification of WHO 2022 bladder tumors.
    Pathologica. 2022;115:32-40.
    PubMed         Abstract available

    Pediatr Blood Cancer

  65. FUJIKI T, Sakai Y, Ikawa Y, Takenaka M, et al
    Pediatric inflammatory myofibroblastic tumor of the bladder with ALK-FN1 fusion successfully treated by alectinib.
    Pediatr Blood Cancer. 2023;70:e30172.
    PubMed         Abstract available

    Plant Foods Hum Nutr

  66. ALTIERI MA, Sarmiento-Machado LM, Romualdo GR, de Moura NA, et al
    Dietary Capsaicin Reduces Chemically Induced Rat Urinary Bladder Carcinogenesis.
    Plant Foods Hum Nutr. 2023;78:93-99.
    PubMed         Abstract available

    PLoS One

  67. WEINBERG L, Aitken SAA, Kaldas P, Fletcher L, et al
    Postoperative complications and hospital costs following open radical cystectomy: A retrospective study.
    PLoS One. 2023;18:e0282324.
    PubMed         Abstract available

    Pol Arch Intern Med

  68. BALAWENDER K, Wawrzyniak A, Walocha J, Mazur M, et al
    Leiomyoma: a case of a rare benign mesenchymal neoplasm of the urinary bladder.
    Pol Arch Intern Med. 2023;133:16381.

    Radiother Oncol

  69. DE HAAR-HOLLEMAN A, van Hoogstraten LMC, C C M Hulshof M, Tascilar M, et al
    Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: a nationwide cohort study.
    Radiother Oncol. 2023 Feb 28:109584. doi: 10.1016/j.radonc.2023.109584.
    PubMed         Abstract available

    Retin Cases Brief Rep

  70. LENTZSCH AM, Siggel R, Schnorr C, Holtick U, et al
    Retin Cases Brief Rep. 2023;17:105-110.
    PubMed         Abstract available

    Scand J Urol

  71. KARTTUNEN E, Hervonen P, Hosseini Aliabad A, Oldenburg J, et al
    Incidence, mortality and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic countries between 1990 and 2019.
    Scand J Urol. 2023;57.
    PubMed         Abstract available

    Register-based research. Accurate data and analysis, crucial for correct conclusions. Comment on "Incidence, mortality, and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic countries between 1990 and 20
    Scand J Urol. 2023;57.

    Sci Adv

  73. AN HW, Hou DY, Yang J, Wang ZQ, et al
    A bispecific glycopeptide spatiotemporally regulates tumor microenvironment for inhibiting bladder cancer recurrence.
    Sci Adv. 2023;9:eabq8225.
    PubMed         Abstract available

    Technol Cancer Res Treat

  74. MAZZASCHI G, Giudice GC, Coriano M, Campobasso D, et al
    Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario.
    Technol Cancer Res Treat. 2023;22:15330338231159753.
    PubMed         Abstract available

    Tohoku J Exp Med

  75. GAO S, Zhou XQ, Wu Q, Chen XD, et al
    Effects of Holliday Junction-Recognition Protein-Mediated C-Jun N-Terminal Kinase/ Signal Transducer and Activator of Transcription 3 Signaling Pathway on Cell Proliferation, Cell Cycle and Cell Apoptosis in Bladder Urothelial Carcinoma.
    Tohoku J Exp Med. 2023;259:209-219.
    PubMed         Abstract available

    Urol Case Rep

  76. KOKURA K, Watanabe J, Takuma T, Uketa S, et al
    A case of Avelumab response to multiple bone and lymph node metastases of plasmacytoid variant bladder cancer.
    Urol Case Rep. 2023;47:102358.
    PubMed         Abstract available

    Urol Oncol

  77. LIU Y, Zhao YC, Lu Y, Goodarz D, et al
    The role of smoking in explaining racial/ethnic disparities in bladder cancer incidence in the United States.
    Urol Oncol. 2023 Feb 25:S1078-1439(23)00051.
    PubMed         Abstract available


  78. GUPTA P, Sarangi SS, Singh M, Pandey H, et al
    To determine correlation between VIRADS scoring and pathological staging in bladder cancer: A prospective study and review of literature.
    Urologia. 2023 Feb 27:3915603231151738. doi: 10.1177/03915603231151738.
    PubMed         Abstract available

    World J Surg Oncol

  79. HE HL, Lai HY, Chan TC, Hsing CH, et al
    Low expression of ZSCAN4 predicts unfavorable outcome in urothelial carcinoma of upper urinary tract and urinary bladder.
    World J Surg Oncol. 2023;21:62.
    PubMed         Abstract available

  80. CINAR NB, Yilmaz H, Avci IE, Cakmak K, et al
    Reporting perioperative complications of radical cystectomy: the influence of using standard methodology based on ICARUS and EAU quality criteria.
    World J Surg Oncol. 2023;21:58.
    PubMed         Abstract available

    World J Urol

  81. HEKMAN MCH, Wijn SRW, Lotan Y, Govers TM, et al
    Bladder EpiCheck urine test in the follow-up of NMIBC: a cost analysis.
    World J Urol. 2023;41:471-476.
    PubMed         Abstract available

  82. DUQUESNE I, Benamran D, Masson-Lecomte A, De La Taille A, et al
    Intraoperative complication of radical cystectomy for muscle-invasive bladder cancer: does the surgical approach matter? A retrospective multicenter study using the EAUiaiC classification.
    World J Urol. 2023 Feb 27. doi: 10.1007/s00345-023-04340.
    PubMed         Abstract available

  83. PETEINARIS A, Kallidonis P, Tsaturyan A, Pagonis K, et al
    The feasibility of robot-assisted radical cystectomy: an experimental study.
    World J Urol. 2023;41:477-482.
    PubMed         Abstract available

  84. FRANCO N, Godono A, Clari M, Ciocan C, et al
    Occupational asbestos exposure and urinary bladder cancer: a systematic review and meta-analysis.
    World J Urol. 2023 Feb 27. doi: 10.1007/s00345-023-04327.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.